S'abonner

Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018 - 14/10/22

Doi : 10.1016/j.jaad.2022.04.058 
Erin M. Warshaw, MD, MS a, b, c, Michelle Xiong, BS a, d, , Amber R. Atwater, MD e, Joel G. DeKoven, MD, MHSc f, Melanie D. Pratt, MD g, Howard I. Maibach, MD h, James S. Taylor, MD i, Donald V. Belsito, MD j, Jonathan I. Silverberg, MD, PhD k, Margo J. Reeder, MD l, Kathryn A. Zug, MD m, Denis Sasseville, MD n, Joseph F. Fowler, MD o, Vincent A. DeLeo, MD p, Marie-Claude Houle, MD q, Cory A. Dunnick, MD r
a Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota 
b Department of Dermatology, University of Minnesota, Minneapolis, Minnesota 
c Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 
d Warren Alpert Medical School of Brown University, Providence, Rhode Island 
e Department of Dermatology, Duke University Medical Center, Durham, North Carolina 
f Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada 
g Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada 
h Department of Dermatology, University of California San Francisco, San Francisco, California 
i Department of Dermatology, Cleveland Clinic, Cleveland, Ohio 
j Department of Dermatology, Columbia University Irving Medical School, New York, New York 
k Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 
l Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 
m Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 
n Division of Dermatology, Montreal General Hospital, McGill University, Montreal, Québec, Canada 
o Division of Dermatology, University of Louisville, Louisville, Kentucky 
p Department of Dermatology, Keck School of Medicine, Los Angeles, California 
q Division of Dermatology, Centre Hospitalier Universitaire Québec, Laval University, Laval, Québec, Canada 
r Department of Dermatology, University of Colorado, Aurora, Colorado 

Correspondence to: Michelle Xiong, BS, Park Nicollet Contact Dermatitis Clinic, 7550 34th Ave S, Suite #101, Minneapolis, MN 55450.Park Nicollet Contact Dermatitis Clinic7550 34th Ave S, Suite #101MinneapolisMN55450

Abstract

Background

Alkyl glucosides are nonionic surfactants that are increasingly used in personal care products.

Objective

To characterize positive patch test reactions to decyl glucoside (5% petrolatum, tested 2009-2018) and lauryl glucoside (3% petrolatum, tested 2017-2018).

Methods

Retrospective analysis of patients tested by the North American Contact Dermatitis Group.

Results

Of 24,097 patients patch tested to decyl and/or lauryl glucoside, 470 (2.0%) had positive reactions. Compared with glucoside-negative patients, glucoside-positive patients had higher odds of occupational skin disease (13.4% vs 10.1%; P = .0207), history of hay fever (38.5% vs 31.6%; P = .0014), atopic dermatitis (39.0% vs 28.6%; P < .0001), and/or asthma (21.8% vs 16.5%; P = .0023). Most glucoside reactions (83.9%) were currently relevant. The most common source was personal care products (63.0%), especially hair products (16.5%) and skin cleansers (15.2%). Of 4933 patients tested to decyl and lauryl glucoside, 134 (2.7%) were positive to 1 or both; 43.4% (43 of 99) of decyl-positive patients were also positive to lauryl glucoside and 55.1% (43/78) of lauryl glucoside patients were also positive to decyl glucoside.

Limitations

The cohort predominantly reflects a referral population, and follow-up after testing was not captured.

Conclusion

Glucoside positivity occurred in 2.0% of the tested patients. Reactions were often clinically relevant and linked to personal care products. Cross-reactivity was >40%.

Le texte complet de cet article est disponible en PDF.

Key words : allergic contact dermatitis, contact allergy, decyl glucoside, glucoside, lauryl glucoside, patch test

Abbreviations used : CAMP, NACDG, OR, PCP


Plan


 Funding sources: Supported by resources and use of facilities at Park Nicollet/Health Partners.
 IRB approval status: Approved by the Health Partners institutional review board.
 Reprints not available from the authors.


© 2022  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 87 - N° 5

P. 1033-1041 - novembre 2022 Retour au numéro
Article précédent Article précédent
  • Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018
  • Amber Reck Atwater, Raina Bembry, Beiyu Liu, Erin M. Warshaw, Joel G. DeKoven, Jonathan I. Silverberg, James S. Taylor, Kathryn A. Zug, Marie-Claude Houle, Donald V. Belsito, Howard I. Maibach, Margo J. Reeder, Denis Sasseville, Cory Dunnick, Joseph F. Fowler, Melanie D. Pratt, Vincent A. DeLeo
| Article suivant Article suivant
  • The immediate patch test reaction to fragrance in patients with allergic contact dermatitis to fragrance: A prospective study
  • Nutchaya Amornruk, Noppachai Siranart, Prattana Sittiwattanawong, Patipark Kueanjinda, Suwimon Loplumlert, Jongkonnee Wongpiyabovorn

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.